Schizophrenia News and Research

Latest Schizophrenia News and Research

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Biotie announced today that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie.

28 Aug 2009

Rutgers University Professor receives $3.5 million MERIT Award from NIH

Rutgers University Professor Dipak Sarkar has received a $3.5 million MERIT Award from the National Institutes of Health (NIH) to continue researching the damaging effects of alcohol on the nervous systems of the unborn.

27 Aug 2009

Researchers find the method involved in setting up communications network of connections in the brain

In a new study, researchers at the Montreal Neurological Institute and Hospital (The Neuro), McGill University have found an important mechanism involved in setting up the vast communications network of connections in the brain.

27 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

UCLA's Laboratory of Neuro Imaging awarded $1.9 million NIH ARRA grant

UCLA researchers have received 80 American Recovery and Reinvestment Act of 2009 (Recovery Act) grants totaling $19.4 million from the National Institutes of Health thus far. UCLA's largest NIH ARRA grant to date was $1.9 million, awarded to UCLA's Laboratory of Neuro Imaging (LONI), which is dedicated to creating scientific approaches to mapping how the brain is structured and how it works.

24 Aug 2009

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.

24 Aug 2009

FDA issues complete response letter regarding the NDA for carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

23 Aug 2009

Cortex Pharmaceuticals receives delisting notification from NYSE Amex

Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company’s plan to regain compliance with the Exchange’s continued listing standards, as submitted by the Company in June.

21 Aug 2009

Aryx Therapeutics reports Q2 2009 financials

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided a general business update for the second quarter ended June 30, 2009.

13 Aug 2009

Sleep patterns can identify adolescents at greatest risk for depression

Sleep patterns can help predict which adolescents might be at greatest risk for developing depression, a researcher at UT Southwestern Medical Center has found in a five-year study.

13 Aug 2009

Anti-psychotic drugs could help treat some major cancers

The observation that people taking medication for schizophrenia have lower cancer rates than other people has prompted new research revealing that anti-psychotic drugs could help treat some major cancers.

12 Aug 2009

Discovery of genetic mutations that increase risk of schizophrenia

In collaboration with colleagues from across Europe, researchers from the University of Copenhagen and the Mental Health Services in the Capital Region of Denmark have found mutations in the human genome that lead to an increased risk of developing schizophrenia.

11 Aug 2009

Landmark legislation brings much-needed reform to New Jersey

New Jersey significantly reformed its mental illness treatment law on August 11th when Governor Corzine signed Senate Bill 735 into law. Senator Richard Codey and countless advocates battled for years to give New Jersey a way to better help those who refuse treatment because of incapacitating symptoms of illnesses like schizophrenia and bipolar disorder. “Our goal is to minimize time in the hospital and keep patients in the least restrictive environment that will help foster their recovery,” said Codey.

11 Aug 2009

Research shows how schizophrenia works in the brain

Schizophrenia waits silently until a seemingly normal child becomes a teenager or young adult. Then it swoops down and derails a young life.

11 Aug 2009

Decode Genetics announces Q2 2009 financials

deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).

10 Aug 2009

High levels of glutamate in brain linked to depression, low cognitive function

Researchers at the Joslin Diabetes Center and several other institutions have for the first time linked high levels of glutamate – a neurotransmitter in the brain produced from glucose – in people with type 1 diabetes to symptoms of depression and lower levels of cognitive performance. The findings may lead to a better understanding of the underlying mechanisms of these conditions in people with diabetes.

4 Aug 2009

Antidepressant use becoming more common in the United States

A marked and broad expansion in antidepressant treatment occurred among Americans older than 6 years between 1996 and 2005, although treatment rates remain low among racial and ethnic minorities, according to a report in the August issue of Archives of General Psychiatry.

4 Aug 2009

FDA approves Invega Sustenna for schizophrenia

The U.S. Food and Drug Administration today approved Invega Sustenna (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.

2 Aug 2009

Maternal exposure to nanoparticles related to neurological dysfunction in the mouse

Maternal exposure to nanoparticles of titanium dioxide (TiO2) affects the expression of genes related to the central nervous system in developing mice. Researchers writing in BioMed Central's open access journal Particle and Fibre Toxicology found that mice whose mothers were injected with the nanoparticles while pregnant showed alteration in gene expression related to neurological dysfunction.

28 Jul 2009